Table 1.
Cumulative Survival Following Trans-arterial Chemo-embolization in Advanced Hepatocellular Carcinoma.
| Study |
Number of patients |
Survival (%) |
||
|---|---|---|---|---|
| 1 year | 2 years | |||
| TACE {Gelfoam powder, doxorubicin [50 mg]} | Pelletier etal71 (J Hepatol, 1990) | 21 | 24 | NR |
| TACE {Gelfoam particles, cisplatin [70 mg]} | Group d'Etude de Traitment du Carcinome He'patocellulare30 (N Engl J Med, 1995) | 50 | 62 | 38 |
| TACE {Gelfoam, cisplatin [2 mg/kg]} | Pelletier et al75 (J Hepatol, 1998) | 37 | 51 | 24 |
| TACE {Gelfoam, cisplatin [maximum 30 mg]} | Lo et al31 (Hepatology, 2002) | 40 | 57 | 31 |
| TACE {Gelfoam, doxorubicin [25–75 mg/m2] | Llovet et al13 (Lancet, 2002) | 40 | 82 | 63 |
| TACE {Lipiodol, anticancer agent, gelatin sponge} | Takayasu et al19 (Gastroenterology, 2006) | 8510 | 82 | 47 (3 years) |
| TACE {Lipodol, Mitomycin C 10 mg} | Herber et al74 (Rofo, 2007) | 94 | 71.6 | 33.9 |
| TACE {doxorubicin 50 mg, cisplatin 100 mg, 10–20 ml of lipiodol, gelfoam} | Paul et al76 (Indian J Radiol Imaging, 2011) | 71 | 60.8 | 34.4 |
NR = not reported.